SLXN — Silexion Therapeutics Corp

—
Nasdaq · Health Care · Biotechnology · CIK 2022416 ·
Last close
$1.65
Market Cap
$1.07M
52W High
$777.12
52W Low
$1.61
ADV30
58,416
Next earnings
—
Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,680,000 -3,551,000 4,246,000 2,229,000 4,202,000
Mar 2026 0 — -2,749,000 -2,733,000 4,602,000 2,413,000 4,311,000
Dec 2025 0 — -4,406,000 -4,412,000 7,215,000 5,991,000 4,612,000
Sep 2025 0 — -3,292,000 -3,262,000 11,614,000 9,243,000 4,637,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,430,000
Investing CF
$-8,000
Financing CF
$11,226,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-85.66
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-61,450,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-14,093,000
Pretax Income TTM
$-13,958,000
Interest Exp TTM
$19,000
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -11,632,000 -11,912,000 7,215,000 4,612,000 2,603,000 -10,819,000
Dec 2024 0 -12,571,000 -16,443,000 2,863,000 6,852,000 -3,989,000 -8,396,000
Dec 2023 0 -4,681,000 -4,942,000 5,256,000 17,312,000 -15,476,000 -4,529,000
Dec 2022 0 -3,860,000 -3,215,000 9,333,000 16,412,000 -10,665,000 -3,335,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$13,958,000
OpCashFlow TTM
—
Assets (Latest)
$4,246,000
Forward EPS
$-0.64

Peers — same industry

TickerNameMarket CapLastDaily %
AGTX Agentix Corp. $1.35M $0.03 —
GPLB Green Planet Bio Engineering Co. Ltd. $580.2K $0.03 —
CLDI Calidi Biotherapeutics, Inc. $2.06M $0.56 —
CPMV Mosaic ImmunoEngineering Inc. $550.4K $0.08 —
VIVS VivoSim Labs, INC. $2.44M $0.12 —

News headlines (Yahoo Finance, 1h cache)

Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-13 14:04 · Yahoo
Silexion Therapeutics Announces 1-for-24 Reverse Share Split
2026-11-09 12:00 · Yahoo
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
2026-09-30 12:00 · Yahoo
Silexion Therapeutics Announces Exercise of Warrants
2026-09-29 12:03 · Yahoo
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
2026-09-28 12:30 · Yahoo
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
2026-09-09 13:00 · Yahoo
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 12:45 · Yahoo
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
2026-08-04 13:15 · Yahoo
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
2026-07-29 11:00 · Yahoo
Silexion Therapeutics to Attend BIO International Convention 2026
2026-06-16 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.